Brief Review and a Clinical Case of Hemolytic Uremic Syndrome Associated with Interferon ß Treatment.
Blood Purif
; 43(1-3): 136-143, 2017.
Article
em En
| MEDLINE
| ID: mdl-27951532
ABSTRACT
The hemolytic uremic syndrome (HUS) is one of the thrombotic microangiopathies and it consists of the triad of nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The atypical form of HUS (aHUS) is related to causative mutations in complement genes. Some conditions act as a trigger for aHUS in individuals that have a genetic background predisposing to complement activation. Interferon ß is a recombinant-protein therapy approved to treat multiple sclerosis (MS), and can be a causative agent in the occurrence of HUS through anti-angiogenic activity. In this paper, we briefly review aHUS clinical and genetic characteristics. Furthermore, we present a case of a 48-year-old woman, diagnosed with MS and treated with INFß-1b from 2008. In December 2015, she presented with asthenia and loss of muscular strength in the legs and she quickly developed aHUS. Our case suggests that INFß is a possible triggering factor for HUS.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interferon beta
/
Síndrome Hemolítico-Urêmica
/
Esclerose Múltipla
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Blood Purif
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Itália